B
Bullisch
Bullisch · 25%NERV
$2.51
Szenariopreis
$2.300
-0.242 (-10.51%)Zum Schluss
Loading chart…
- Hoch
- 2.660
- Eröffnung
- 2.660
- Volumengewichteter Durchschnittskurs
- 2.42
- Volumen
- 182.09K
- Marktkap.
- 21.33M
- Tief
- 2.290
- Umsatz
- 440.06K
- EV/EBITDA, TTM
- 0.00
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
KI-Analyse of Minerva Neurosciences Inc (NERV)
HaltenMinerva Neurosciences Inc (NERV) is currently trading at $2.345, which is significantly below its 52-week high of $8.80, indicating potential upside. However, the company has a negative earnings per share (EPS) of -0.14 expected for the next quarter and a recent trend of declining revenues, with a 20-day change of -29.37%. The RSI is at 46.487, suggesting the stock is neither overbought nor oversold. Given the high volatility and recent earnings miss, it may be prudent to hold rather than buy at this time.
Analystenbewertungen (3)
+95.65% Aufwärtspotenzial
Kaufen
3 Kaufen
0 Halten
0 Verkaufen
Aktuell: 2.30
Tief
4.00
Durchschnitt
4.50
Hoch
5.00
Citizens
Überdurchschnittlich
$14
2026-04-15
Citizens
2026-04-15
Kursziel
$14
Überdurchschnittlich
H.C. Wainwright
Neutral
$7
2026-03-12
H.C. Wainwright
2026-03-12
Kursziel
$7
Neutral
H.C. Wainwright
Neutral
$4
2025-11-06
H.C. Wainwright
2025-11-06
Kursziel
$4
Neutral
HC Wainwright & Co.
Halten
$5
2025-02-26
HC Wainwright & Co.
2025-02-26
Kursziel
$5
Halten
HC Wainwright & Co.
Halten
$5
2024-11-06
HC Wainwright & Co.
2024-11-06
Kursziel
$5
Halten
Bewertungskennzahlen
Das aktuelle erwartete KGV von Minerva Neurosciences Inc (NERV) beträgt 11.21, verglichen mit dem 5-Jahres-Durchschnitt von 4.98.
Alphio-AI-Kursszenarien für NERV
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die NERV halten
Event-Zeitleiste
News
1.008-28NewsfilterMinerva Neurosciences to Participate in Upcoming Investor Conferences
- 9.008-07Newsfilter
Minerva Advances Roluperidone Phase 3 Trial for Schizophrenia Symptoms
- 9.505-05seekingalpha
Minerva Neurosciences Q1 Earnings Report
8.504-15seekingalphaMinerva Neurosciences Gains on Market Outperform Rating for Roluperidone
8.503-11seekingalphaMinerva Neurosciences Files $200M Shelf Registration for Securities Offering
NERV FAQ – beantwortet von Alphio AI
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Minerva Neurosciences Inc (NERV) is currently trading at $2.345, which is significantly below its 52-week high of $8.80, indicating potential upside. However, the company has a negative earnings per share (EPS) of -0.14 expected for the next quarter and a recent trend of declining revenues, with a 20-day change of -29.37%. The RSI is at 46.487, suggesting the stock is neither overbought nor oversold. Given the high volatility and recent earnings miss, it may be prudent to hold rather than buy at this time.
3 analysts cover NERV: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.50.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenÄhnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.